Cargando…

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer

BACKGROUND. Liquid biopsies have demonstrated that the constitutively active androgen receptor splice variant-7 (AR-V7) associates with reduced response and overall survival from endocrine therapies in castration-resistant prostate cancer (CRPC). However, these studies provide little information per...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharp, Adam, Coleman, Ilsa, Yuan, Wei, Sprenger, Cynthia, Dolling, David, Rodrigues, Daniel Nava, Russo, Joshua W., Figueiredo, Ines, Bertan, Claudia, Seed, George, Riisnaes, Ruth, Uo, Takuma, Neeb, Antje, Welti, Jonathan, Morrissey, Colm, Carreira, Suzanne, Luo, Jun, Nelson, Peter S., Balk, Steven P., True, Lawrence D., de Bono, Johann S., Plymate, Stephen R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2018
Materias:	Clinical Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307949/ https://www.ncbi.nlm.nih.gov/pubmed/30334814 http://dx.doi.org/10.1172/JCI122819

Ejemplares similares

Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer
por: Uo, Takuma, et al.
Publicado: (2020)

Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
por: Sowalsky, Adam G., et al.
Publicado: (2022)

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
por: Welti, Jonathan, et al.
Publicado: (2016)

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
por: Zhang, Xiaotun, et al.
Publicado: (2011)

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
por: Paschalis, Alec, et al.
Publicado: (2019)

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
por: Nghiem, Belinda, et al.
Publicado: (2016)

MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand
por: Liu, Gang, et al.
Publicado: (2014)

Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain
por: Uo, T, et al.
Publicado: (2017)

Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer
por: Choi, Stephen Y. C., et al.
Publicado: (2022)

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer
por: Zadra, Giorgia, et al.
Publicado: (2019)

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
por: Henzler, Christine, et al.
Publicado: (2016)

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
por: Kolinsky, M.P., et al.
Publicado: (2020)

Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
por: Coleman, Ilsa M., et al.
Publicado: (2022)

Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer
por: Sheehan, Beshara, et al.
Publicado: (2022)

Intracrine androgen biosynthesis and drug resistance
por: Penning, Trevor M., et al.
Publicado: (2020)

Genomics of lethal prostate cancer at diagnosis and castration resistance
por: Mateo, Joaquin, et al.
Publicado: (2020)

Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling
por: Brady, Lauren, et al.
Publicado: (2021)

Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
por: Nyquist, Michael D., et al.
Publicado: (2023)

Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling
por: Nguyen, Holly M., et al.
Publicado: (2013)

Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer
por: Grochot, Rafael, et al.
Publicado: (2023)

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
por: Pezaro, C, et al.
Publicado: (2013)

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents
por: Crespo, M, et al.
Publicado: (2015)

Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer
por: Cato, Laura, et al.
Publicado: (2017)

HER3 Is an Actionable Target in Advanced Prostate Cancer
por: Gil, Veronica, et al.
Publicado: (2021)

Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
por: Zhang, Ailin, et al.
Publicado: (2023)

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
por: Mehra, Niven, et al.
Publicado: (2018)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Polycomb-independent activity of EZH2 in castration resistant prostate cancer
por: Xu, Kexin, et al.
Publicado: (2013)

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
por: Bianchini, D, et al.
Publicado: (2013)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
por: Mateo, Joaquin, et al.
Publicado: (2020)

Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer
por: Asangani, Irfan, et al.
Publicado: (2021)

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
por: Lorente, David, et al.
Publicado: (2016)

Control of androgen receptor action by a novel nuclear receptor binding motif in Bag-1L
por: Cato, Laura, et al.
Publicado: (2013)

The androgen receptor mediates antiapoptotic function in myometrial cells
por: Li, H, et al.
Publicado: (2014)

The Effects of Aging on the Molecular and Cellular Composition of the Prostate Microenvironment
por: Bianchi-Frias, Daniella, et al.
Publicado: (2010)

Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer
por: Han, Wanting, et al.
Publicado: (2022)

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers
por: Rescigno, Pasquale, et al.
Publicado: (2018)

Androgen receptor epigenetics
por: Cai, Changmeng, et al.
Publicado: (2013)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_djo44crnm5cltqjbda8q2075bk